The regulatory environment in China, guided by the NMPA, appears to be evolving positively, providing a conducive framework for pharmaceutical innovation and growth
In Conversation
We've strived for a culture rooted in fairness, transparency, and hard work
We recognize the substantial unmet medical needs in China and the growing potential of local innovation to drive global advancements
We are a global CDMO committed to delivering exceptional value and quality to our clients. Our extensive experience in meeting the stringent quality standards of global…
While we have already received approval for three products in China, our revenue aspirations extend beyond domestic markets
As multinational companies, we must not only localize our operations but also recognize and leverage the unique strengths and perspectives of our Chinese counterparts
True biotech isn't about managing portfolios like big pharma does. It's about addressing unmet medical needs where there's a clinical void that larger pharmaceutical companies haven't…
The transition to annual updates [of China's National Reimbursement Drug List] has greatly enhanced patient access to innovative drugs, reflecting positive changes in the regulatory landscape
The drug discovery industry is moving into a different, technology- and engineering-driven, phase. This favours China, which is very good at engineering and assembling novel molecules…
Cultural alignment and trust are paramount considerations when exploring collaborations or investments in the Chinese biotech sector
We need partners who understand that our mission is more than a business
After so many years of globalization, it is clear that we are interdependent and interconnected. Cutting off the channels of cooperation would lead to harm on…
